RecruitingNCT04743674

Blood and Urine HPVDNA as Minimally Invasive Biomarkers for Cervical Cancer Detection and Surveillance Following Treatment

Plasma Circulating Tumor HPVDNA and Transrenal HPVDNA as Minimally Invasive Biomarkers for Cervical Cancer Detection and Surveillance Following Definitive Treatment

Sponsor

UNC Lineberger Comprehensive Cancer Center

Enrollment

30 participants

Start Date

May 3, 2024

Study Type

OBSERVATIONAL

Conditions

Cervical Cancer

Summary

The purpose of this study is to determine if ctHPVDNA (circulating tumor HPV DNA) can be used as a non-invasive biomarker for identification and treatment monitoring of cervical cancer by characterizing correlation between plasma ctHPVDNA, urine transrenal HPVDNA (TrHPVDNA) levels and presence of cervical cancer at diagnosis and following definitive intent management.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether HPV DNA found in blood or urine can serve as a simple, non-invasive way to detect cervical cancer and track whether treatment is working — without the need for invasive procedures. **You may be eligible if...** - You are 18 years or older - You have a new diagnosis of cervical cancer - You are willing and able to comply with the study procedures **You may NOT be eligible if...** - You are currently pregnant - You are unable to attend study visits or follow the study requirements - Your cervical cancer has been previously treated Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.